Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 vs Tiotropium in Brazilian COPD Patients
NCT01837927Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 12 weeks. Planned start Apr 2014; status: withdrawn.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01837927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01837927.